e-Article
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.
Document Type
Journal Article
Author
Attard, G; Clark, J; Ambroisine, L; Mills, I G; Fisher, G; Flohr, P; Reid, A; Edwards, S; Kovacs, G; Berney, D; Foster, C; Massie, C E; Fletcher, A; De Bono, J S; Scardino, P; Cuzick, J; Cooper, C S; Transatlantic Prostate Group (CORPORATE AUTHOR)
Source
Subject
*DIAGNOSIS
*PROSTATE cancer
*CANCER patients
*PROSTATE
*MALE reproductive organs
*FLUORESCENCE in situ hybridization
*RNA
*SURGICAL excision
*CHROMOSOME abnormalities
*COMPARATIVE studies
*ENZYMES
*GENES
*GENETICS
*HISTOLOGICAL techniques
*LONGITUDINAL method
*RESEARCH methodology
*MEDICAL cooperation
*POLYMERASE chain reaction
*PROSTATE tumors
*RESEARCH
*RESEARCH funding
*TRANSCRIPTION factors
*DNA-binding proteins
*EVALUATION research
*REVERSE transcriptase polymerase chain reaction
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0007-0920
Abstract
A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer. [ABSTRACT FROM AUTHOR]